Plain-English translation of NCT06443307 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →This real-world study is testing how well liposome irinotecan (Nal-IRI) works in treating advanced colorectal cancer and other solid tumors. Rather than a strictly controlled lab environment, researchers will follow patients receiving this medication as part of their normal cancer care across multiple hospitals in China. The study aims to understand both how effective the medication is and what side effects patients experience.
Doctors need to understand how this medication performs when used in everyday clinical practice—not just in controlled research settings. This information will help them decide when and how to use the treatment for different groups of cancer patients.
You likely qualify if…
You likely don't qualify if…
Participation follows your normal cancer care schedule and visits with your oncologist—there are no special research-only appointments. You will receive the medication as part of your standard treatment plan, and your doctor will monitor you with regular exams and imaging scans. Researchers will collect information about how you respond to treatment and any side effects you experience, but your care is guided by what your doctor believes is best for you, not a rigid study protocol.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China